Intellia Therapeutics (NTLA)
(Real Time Quote from BATS)
$27.10 USD
+0.68 (2.57%)
Updated Jul 26, 2024 09:48 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 121 - 140 ( 289 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Provides Updates on Strategic Priorities and Development Milestones for 2022; Sets Stage for Catalyst Rich-Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Forms Strategic Partnership With Kyverna to Tackle B Cell-Mediated Autoimmune Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As CAR-T Programs Scream "Look at Me" During ASH, We Look to the Future Impact of TCR-Ts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Therapeutics Announces Dosing of First Patient in Phase 1/2 Study of NTLA-2002 for the Treatment of HAE
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Catalysts from Our Coverage Universe: YE2021 and Beyond
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase I Study for NTLA-2001 Expands to Include ATTR
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Second In Vivo CRISPR Trial for Hereditary Angioedema Posted
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NTLA Reports 3Q21; Announces Upcoming Catalysts, Forms Strategic Partnerships and Advances New Development Candidates
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21: Additional Data From Lead Program in 1Q22
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T